Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Pulmonary surfactant protein and related polypeptides|
|Abstract:||The present invention discloses useful peptides and synthetic pulmonary surfactants, as well as methods of making and using same. In a preferred embodiment, a synthetic pulmonary surfactant comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions. In other embodiments, a surfactant peptide has an amino acid residue sequence selected from the group consisting of KLLLLKLLLLKLLLLKLLLLK, KLLLLLLLLKLLLLLLLLKLL, and KKLLLLLLLKKLLLLLLLKKL.|
|Inventor(s):||Cochrane; Charles G. (La Jolla, CA), Revak; Susan D. (San Diego, CA)|
|Assignee:||The Scripps Research Institute (La Jolla, CA)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||196298||<disabled in preview>|
|Austria||199730||<disabled in preview>|
|Austria||223436||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.